Evaluation of the Preventive Efficacy and Safety of Azoximer Bromide in Healthcare Workers in Contact with Patients Hospitalized for COVID-19

Relevance. Despite the implementation of measures to reduce morbidity and mortality among medical workers who are in contact with patients hospitalized for a new coronavirus infection caused by SARS-CoV-2 (hereinafter – COVID-19), their level remains high today. Given the difficulty of achieving the required number of vaccinated to form collective immunity, the issue of finding additional drug-based ways to prevent COVID-19, especially in risk groups, becomes urgent. Aims. To evaluate the effect of azoximer bromide on the number of cases of confirmed COVID-19 disease among medical workers, as well as on the level of chronic fatigue in the study groups. Materials and methods: 78 men and women were included in the study. The experimental group consisted of 41 people who took azoximer bromide for 38 days. The comparison group consisted of 37 people who were not prescribed azoximer bromide. The epidemiological efficacy of the drug was evaluated. Statistical evaluation of the significance of the differences was carried out using the Student's t-test, Pearson's criterion χ². Results. The number of study participants with COVID-19 in the experimental group was significantly lower than in the comparison group. A significantly faster reduction of manifestations of chronic fatigue syndrome was noted in study participants who took azoximer bromide. There were no adverse events during the administration of the studied drug by the study participants. Conclusions. Azoximer bromide has shown epidemiological efficacy when used by medical workers directly providing medical care to patients with COVID-19 (when working in the «red zone»), including contributing to the more rapid normalization of the psychological state of medical workers

1. World Health Organization. Coronavirus disease (COVID-19) [Internet]. Weekly situational report. Available at: https://www.who.int/emergencies/diseases/novel-coronavi-rus-2019/situation-reports.

2. Wang D., Hu B., Hu C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;23(11):1061–1069. doi:10.1001/jama.2020.1585

3. Ministry of healthcare of the Russian Federation. Vremennye metodicheskie rekomendacii po profilaktike, diagnostike i lecheniyu novoj koronavirusnoj infekcii (COVID-19). Avail- able at: http://static0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v10.pdf. Ссылка активна на 05.08.2021. (In Russ.).

4. Galvis V., Spinelli FR., Tello A., et al. Hydroxychloroquine as prophylaxis for coronavirus SARS-CoV-2 infection: review of the ongoing clinical trials. Archivos De Bronconeumo- logia. 2020;56(9):606–608. doi:10.1016/j.arbres.2020.05.008

5. Mukhopadhyay S., Suhrita P., Basabdatta S. Hydroxychloroquine in the prophylaxis of COVID 19: A survey of safety on the healthcare workers in India. Perspectives in clinical research. 2021;12(1):58–59. doi:10.4103/picr.PICR_310_20

6. World Health Organization. Coronavirus disease (COVID-19): Hydroxychloroquine. Available at: https://www.who.int/news-room/q-a-detail/coronavirus-diseasecovid-19-hydroxychloroquine.

7. Bryant A., Lawrie TA., Dowswell T. et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American journal of therapeutics. 2021;28(4):434–460. doi:10.1097/MJT.0000000000001402

8. Ministry of health of the Russian Federation. Vremennye metodicheskie rekomendacii po lekarstvennoj terapii ostryh respiratornyh virusnyh infekcij (ORVI) v ambulatornoj praktike v period epidemii COVID-19 (versiya 2B 16.04.2020). Available at: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/033/original/RESP_REC_V2.pdf. (In Russ.).

9. World Health organization. Ocenka riskov kontakta s virusom COVID-19 dlya medicinskih rabotnikov i vedenie kontaktirovavshih: vremennoe rukovodstvo ot 4 marta 2020 g. Available at: https://apps.who.int/iris/handle/10665/331725. (In Russ.).

10. Sant’Ana G., Imoto AM., Amorim FF., et al. Infection and death in healthcare workers due to COVID-19: a systematic review. ACTA Paulista de enfermagem. 2020;34. doi:10.37689/acta-ape/2020AO0107.

11. Kostinov M.P., Akhmatova N.K., Khromova E.A., et al. The impact of adjuvanted and non-adjuvanted influenza vaccines on the innate and adaptive immunity effectors. In: Influenza – therapeutics and challenges. London: IntechOpen book series; 2018:83–109.

12. Vavilova V.P., Vavilov A.M., Perevoshikova N.K., et al. Opyt profilaktiki novoj koronavirusnoj infekcii (COVID-19) u medicinskih rabotnikov. Terapiya. 2020;6:93–02. (In Russ.).

13. Luss L. V., Nekrasov A. V., Puchkova N. G. et al. Rol’ immunomoduliruyushchej terapii v obshcheklinicheskoj praktike. Immunologiya. 2000;5:34–38. (In Russ.).

14. Szemiel AM., Merits A., Orton RJ., et al. In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathogens. 2021;17(9). doi: 10.1371/journal.ppat.1009929.

15. Grossi G., Perski A., Evengard B., et al. Physiological correlates of burnout among women. Journal of Psychosomatic Research. 2003;55:309–316. doi: 10.1016/S0022-3999(02)00633-5.

16. Casado A., De Lucas N., Lopez-Fernandez E., et al. Lipid peroxidation, occupational stress and aging in workers of a prehospital emergency service. European Journal of Emergency Medicine. 2006;13:165–170. doi: 10.1097/01.mej.0000194404.61076.88